Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : UCB Pharma S.A
Deal Size : $680.0 million
Deal Type : Divestment
Belgium's UCB to sell China neurology, allergy business for $680 mln
Details : UCB is divesting its mature neurology and allergy business in China, which includes Keppra (levetiracetam), a medication used for the treatment of seizures, to CBC Group.
Product Name : Keppra
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 26, 2024
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : UCB Pharma S.A
Deal Size : $680.0 million
Deal Type : Divestment
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Trevena
Deal Size : $40.0 million
Deal Type : Financing
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
Details : The funding was triggered by the first commercial sale of OLINVYK (oliceridine), contains oliceridine, an opioid, which is a Schedule II controlled substance, indicated in adults for the management of acute pain severe, in China by Jiangsu Nhwa.
Product Name : Olinvyk
Product Type : Miscellaneous
Upfront Cash : $15.0 million
September 06, 2023
Lead Product(s) : Oliceridine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Trevena
Deal Size : $40.0 million
Deal Type : Financing
Lead Product(s) : Azilsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Hasten Biopharmaceutic
Deal Size : $315.0 million
Deal Type : Financing
CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma
Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...
Product Name : Edarbi
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 20, 2023
Lead Product(s) : Azilsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Hasten Biopharmaceutic
Deal Size : $315.0 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Adcentrx Therapeutics
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : Series A financing is raised to power the development of next generation ADC for improving patient treatment options.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 28, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Adcentrx Therapeutics
Deal Size : $50.0 million
Deal Type : Series A Financing
Reset All
